Johnson & Johnson Stock Surges 54% Amid Product Transition
Between late August 2025 and late August 2026, Johnson & Johnson (JNJ) stock surged by 54%, outperforming the S&P 500's 20.5%. This growth was driven not by headline financial metrics but rather a strategic product transition within its immunology portfolio. STELARA faced biosimilar competition and dropped significantly in early 2025, while TREMFYA emerged as a replacement with strong uptake in inflammatory bowel disease indications. By mid-2026, TREMFYA had surged to $2 billion quarterly sales, offsetting the steep decline of STELARA. This shift supported JNJ's overall revenue growth and lifted its operational outlook to an estimated $100.6 billion midpoint for 2026. While other catalysts like regulatory approvals and legal settlements occurred in July 2026, it was TREMFYA’s performance that provided the structural foundation for Johnson & Johnson’s stock re-rating.
Topics: immunology drugs pharmaceuticals revenue growth stock performance